Logo image of LGVN

LONGEVERON INC-A (LGVN) Stock Fundamental Analysis

NASDAQ:LGVN - Nasdaq - US54303L2034 - Common Stock - Currency: USD

1.2353  +0.01 (+0.43%)

Fundamental Rating

3

Overall LGVN gets a fundamental rating of 3 out of 10. We evaluated LGVN against 559 industry peers in the Biotechnology industry. While LGVN seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, LGVN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LGVN had negative earnings in the past year.
LGVN had a negative operating cash flow in the past year.
LGVN had negative earnings in each of the past 5 years.
In the past 5 years LGVN always reported negative operating cash flow.
LGVN Yearly Net Income VS EBIT VS OCF VS FCFLGVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

LGVN has a Return On Assets of -122.67%. This is amonst the worse of the industry: LGVN underperforms 81.93% of its industry peers.
With a Return On Equity value of -149.05%, LGVN is not doing good in the industry: 62.61% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -122.67%
ROE -149.05%
ROIC N/A
ROA(3y)-116.31%
ROA(5y)-85.81%
ROE(3y)-177.95%
ROE(5y)-153.9%
ROIC(3y)N/A
ROIC(5y)N/A
LGVN Yearly ROA, ROE, ROICLGVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 82.29%, LGVN belongs to the top of the industry, outperforming 86.58% of the companies in the same industry.
In the last couple of years the Gross Margin of LGVN has grown nicely.
LGVN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.36%
GM growth 5Y20.42%
LGVN Yearly Profit, Operating, Gross MarginsLGVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

6

2. Health

2.1 Basic Checks

LGVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
LGVN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LGVN has more shares outstanding
LGVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LGVN Yearly Shares OutstandingLGVN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M
LGVN Yearly Total Debt VS Total AssetsLGVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

LGVN has an Altman-Z score of -6.65. This is a bad value and indicates that LGVN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -6.65, LGVN is not doing good in the industry: 65.83% of the companies in the same industry are doing better.
There is no outstanding debt for LGVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.65
ROIC/WACCN/A
WACC9.65%
LGVN Yearly LT Debt VS Equity VS FCFLGVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 5.61 indicates that LGVN has no problem at all paying its short term obligations.
LGVN has a Current ratio (5.61) which is in line with its industry peers.
A Quick Ratio of 5.61 indicates that LGVN has no problem at all paying its short term obligations.
LGVN's Quick ratio of 5.61 is in line compared to the rest of the industry. LGVN outperforms 59.03% of its industry peers.
Industry RankSector Rank
Current Ratio 5.61
Quick Ratio 5.61
LGVN Yearly Current Assets VS Current LiabilitesLGVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

LGVN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.41%, which is quite impressive.
Looking at the last year, LGVN shows a very strong growth in Revenue. The Revenue has grown by 127.51%.
LGVN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -15.76% yearly.
EPS 1Y (TTM)69.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.88%
Revenue 1Y (TTM)127.51%
Revenue growth 3Y22.35%
Revenue growth 5Y-15.76%
Sales Q2Q%-30.47%

3.2 Future

Based on estimates for the next years, LGVN will show a very strong growth in Earnings Per Share. The EPS will grow by 24.91% on average per year.
LGVN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 162.69% yearly.
EPS Next Y68.38%
EPS Next 2Y31.05%
EPS Next 3Y24.91%
EPS Next 5YN/A
Revenue Next Year-3.91%
Revenue Next 2Y9.52%
Revenue Next 3Y162.69%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LGVN Yearly Revenue VS EstimatesLGVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
LGVN Yearly EPS VS EstimatesLGVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LGVN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LGVN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LGVN Price Earnings VS Forward Price EarningsLGVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LGVN Per share dataLGVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as LGVN's earnings are expected to grow with 24.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.05%
EPS Next 3Y24.91%

More info and screens

0

5. Dividend

5.1 Amount

LGVN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LONGEVERON INC-A

NASDAQ:LGVN (6/9/2025, 1:59:13 PM)

1.2353

+0.01 (+0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)N/A N/A
Inst Owners8.72%
Inst Owner Change4.53%
Ins Owners10.02%
Ins Owner Change-0.66%
Market Cap18.54M
Analysts82.22
Price Target9.07 (634.23%)
Short Float %3.93%
Short Ratio3.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.89%
Min EPS beat(2)-23.99%
Max EPS beat(2)-1.78%
EPS beat(4)1
Avg EPS beat(4)-26.8%
Min EPS beat(4)-106.22%
Max EPS beat(4)24.81%
EPS beat(8)2
Avg EPS beat(8)-16.49%
EPS beat(12)2
Avg EPS beat(12)-15.33%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-22.52%
Min Revenue beat(2)-37.77%
Max Revenue beat(2)-7.27%
Revenue beat(4)1
Avg Revenue beat(4)8.31%
Min Revenue beat(4)-37.77%
Max Revenue beat(4)90.89%
Revenue beat(8)2
Avg Revenue beat(8)141.56%
Revenue beat(12)4
Avg Revenue beat(12)100.97%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.14%
PT rev (3m)0.14%
EPS NQ rev (1m)-4.92%
EPS NQ rev (3m)8.57%
EPS NY rev (1m)-5.88%
EPS NY rev (3m)0.38%
Revenue NQ rev (1m)-22.89%
Revenue NQ rev (3m)-37%
Revenue NY rev (1m)-12.71%
Revenue NY rev (3m)-29.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.33
P/FCF N/A
P/OCF N/A
P/B 1.08
P/tB 1.25
EV/EBITDA N/A
EPS(TTM)-2.94
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS0.15
BVpS1.14
TBVpS0.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -122.67%
ROE -149.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.29%
FCFM N/A
ROA(3y)-116.31%
ROA(5y)-85.81%
ROE(3y)-177.95%
ROE(5y)-153.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.36%
GM growth 5Y20.42%
F-Score6
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 97.16%
Cap/Sales 49.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.61
Quick Ratio 5.61
Altman-Z -6.65
F-Score6
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)90.92%
Cap/Depr(5y)89.88%
Cap/Sales(3y)69.8%
Cap/Sales(5y)62.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.88%
EPS Next Y68.38%
EPS Next 2Y31.05%
EPS Next 3Y24.91%
EPS Next 5YN/A
Revenue 1Y (TTM)127.51%
Revenue growth 3Y22.35%
Revenue growth 5Y-15.76%
Sales Q2Q%-30.47%
Revenue Next Year-3.91%
Revenue Next 2Y9.52%
Revenue Next 3Y162.69%
Revenue Next 5YN/A
EBIT growth 1Y13.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.19%
OCF growth 3YN/A
OCF growth 5YN/A